[HTML][HTML] Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
U Laufs, JK Liao - Journal of Biological Chemistry, 1998 - ASBMB
The mechanism by which 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors
increase endothelial nitric oxide synthase (eNOS) expression is unknown. To determine
whether changes in isoprenoid synthesis affects eNOS expression, human endothelial cells
were treated with the HMG-CoA reductase inhibitor, mevastatin (1–10 μm), in the presence
ofl-mevalonate (200 μm), geranylgeranylpyrophosphate (GGPP, 1–10 μm),
farnesylpyrophosphate (FPP, 5–10 μm), or low density lipoprotein (LDL, 1 mg/ml) …
increase endothelial nitric oxide synthase (eNOS) expression is unknown. To determine
whether changes in isoprenoid synthesis affects eNOS expression, human endothelial cells
were treated with the HMG-CoA reductase inhibitor, mevastatin (1–10 μm), in the presence
ofl-mevalonate (200 μm), geranylgeranylpyrophosphate (GGPP, 1–10 μm),
farnesylpyrophosphate (FPP, 5–10 μm), or low density lipoprotein (LDL, 1 mg/ml) …